Toggle Main Menu Toggle Search

Open Access padlockePrints

Browsing publications by Professor Graham Jackson.

Newcastle AuthorsTitleYearFull text
Dr Wei-yu Lin
Dr Sarah Fordham
Dr Nicola Sunter
Dr Claire Elstob
Dr Yaobo Xu
et al.
Author Correction: Genome-wide association study identifies susceptibility loci for acute myeloid leukemia (Nature Communications, (2021), 12, 1, (6233), 10.1038/s41467-021-26551-x)2022
Professor Graham Jackson
Redefining nonmeasurable multiple myeloma using mass spectrometry2022
Professor Graham Jackson
Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial2021
Professor Graham Jackson
Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma - A meta-analysis of 2,596 trial patients2021
Professor Graham Jackson
Copy number evolution and its relationship with patient outcome—an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial2021
Professor Graham Jackson
Professor Marcus Kaiser
Early relapse after high-dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high-risk disease in multiple myeloma2021
Dr Wei-Yu Lin
Dr Sarah Fordham
Dr Nicola Sunter
Dr Claire Elstob
Dr Yaobo Xu
et al.
Genome-wide association study identifies susceptibility loci for acute myeloid leukemia2021
Professor Graham Jackson
Safety of lenalidomide for maintenance treatment of patients with multiple myeloma following autologous stem cell transplantation2021
Professor Graham Jackson
BRAF and DIS3 Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma2020
Professor Graham Jackson
An enhanced genetic model of relapsed IGH-translocated multiple myeloma evolutionary dynamics2020
Dr Laura Jardine
Dr Urszula Cytlak-Chaudhuri
Dr Merry Gunawan
Dr Gary Reynolds
Dr Kile Green
et al.
Donor monocyte-derived macrophages promote human acute graft-versus-host disease2020
Professor Graham Jackson
Excluding myeloma diagnosis using revised thresholds for serum free light chain ratios and M-protein levels2020
Dr Aneta Mikulasova
Professor Graham Jackson
Microhomology-mediated end joining drives complex rearrangements and overexpression of MYC and PVT1 in multiple myeloma2020
Professor Graham Jackson
Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients2020
Professor Graham Jackson
Real-world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID-19 disease) in patients with multiple myeloma receiving systemic anti-cancer therapy2020
Professor Graham Jackson
Renal outcome in patients with newly diagnosed multiple myeloma: Results from the UK NCRI Myeloma XI trial2020
Professor Graham Jackson
The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trial2020
Professor Graham Jackson
Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials2020
Professor Graham Jackson
A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study2019
Professor Graham Jackson
Erratum to: Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma (Nature Communications, (2018), 9, 1, (3707), 10.1038/s41467-018-04989-w)2019
Dr Nicola Sunter
Professor Graham Jackson
Professor James Allan
Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology2019
Professor Graham Jackson
Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial2019
Professor Graham Jackson
Physicians, paraproteins and progress: Diagnosis and management of myeloma2019
Professor Graham Jackson
Transcriptome-wide association study of multiple myeloma identifies candidate susceptibility genes2019
Dr Katherine Sturgess
Dr Rachel Dickinson
Professor Andrew Gennery
Professor Andrew Cant
Professor Graham Jackson
et al.
In vivo T-depleted reduced intensity transplantation for GATA2-related immune dysfunction.2018
Professor Graham Jackson
A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis2018
Professor Graham Jackson
Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials2018
Professor Graham Jackson
Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma2018
Professor Graham Jackson
Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma2018
Dr Urszula Cytlak-Chaudhuri
Dr Anastasia Resteu
Dr Tom Altmann
Professor Andrew Gennery
Professor Graham Jackson
et al.
Ikaros family zinc finger 1 regulates dendritic cell development and function in humans2018
Dr Sarah Fordham
Dr Helen Blair
Dr Claire Elstob
Professor Ruth Plummer
Dr Yvette Drew
et al.
Inhibition of ATR acutely sensitises acute myeloid leukemia cells to nucleoside analogs that target ribonucleotide reductase2018
Professor Graham Jackson
Maintenance Treatment and Survival in Patients with Myeloma: A Systematic Review and Network Meta-Analysis2018
Professor Graham Jackson
Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network2018
Professor Graham Jackson
Quality of life during and following sequential treatment of previously untreated patients with multiple myeloma: findings of the Medical Research Council Myeloma IX randomised study2018
Professor Graham Jackson
Subclonal TP53 copy number is associated with prognosis in multiple myeloma2018
Professor Graham Jackson
Active multiple myeloma suppresses and typically eliminates coexisting MGUS2017
Professor Graham Jackson
Assessing the effect of obesity-related traits on multiple myeloma using a Mendelian randomisation approach2017
Professor Graham Jackson
Diagnosis and monitoring for light chain only and oligosecretory myeloma using serum free light chain tests2017
Dr Nicola Sunter
Dr Andrew Hall
Dr Tryfonia Mainou-Fowler
Professor Graham Jackson
Dr Helen Marr
et al.
Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia2017
Dr Nicola Sunter
Professor Graham Jackson
Dr Thahira Rahman
Professor James Allan
Genome-wide association analysis of chronic lymphocytic leukaemia, Hodgkin lymphoma and multiple myeloma identifies pleiotropic risk loci2017
Dr Kile Green
Dr Kim Pearce
Dr Laura Jardine
Dr Venetia Bigley
Professor Graham Jackson
et al.
Impact of Alemtuzumab Scheduling on Graft-versus-Host Disease after Unrelated Donor Fludarabine and Melphalan Allografts2017
Professor Graham Jackson
Neutral tumor evolution in myeloma is associated with poor prognosis2017
Professor Graham Jackson
Response comparison of multiple myeloma and monoclonal gammopathy of undetermined significance to the same anti-myeloma therapy: a retrospective cohort study2017
Professor Graham Jackson
Professor James Allan
Telomere length is a critical determinant for survival in multiple myeloma2017
Dr Aneta Mikulasova
Professor Graham Jackson
The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma2017
Professor Graham Jackson
The varied distribution and impact of RAS codon and other key DNA alterations across the translocation cyclin D subgroups in multiple myeloma2017
Professor Graham Jackson
Deletion of CDKN2C drives the prognostic impact of deletion 1P in multiple myeloma2016
Professor Graham Jackson
DYNAMIC EVOLUTION OF COPY NUMBER ABERRATIONS ACCOMPANIES DISEASE RELAPSE IN MULTIPLE MYELOMA2016
Dr Gail Jones
Professor Graham Jackson
Evolving concepts in tumour lysis syndrome management - response to Ayed et al2016
Professor Graham Jackson
Genetic factors influencing the risk of multiple myeloma bone disease2016
Professor Graham Jackson
Genome-wide association study identifies multiple susceptibility loci for multiple myeloma2016
Professor Graham Jackson
Genome-wide association study identifies variation at 6q25.1 associated with survival in multiple myeloma2016
Dr Kim Pearce
Jean Norden
Professor Graham Jackson
Professor Anne Dickinson
Impact of genomic risk factors on survival after haematopoietic stem cell transplantation for patients with acute leukaemia2016
Professor Graham Jackson
Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimen2016
Professor Graham Jackson
Minimal residual disease predicts outcome in transplant ineligible myeloma patients: Results from the UK NCRI Myeloma XI trial2016
Professor Graham Jackson
Patients in the MRC Myeloma XI trial receiving induction chemotherapy for newly diagnosed multiple myeloma containing dexamethasone at full or moderated dose have significantly reduced half-life of IgG2016
Ka Lee
Becky Swan
Dr Ian Cowell
Professor Graham Jackson
Professor Caroline Austin
et al.
Proteasomal inhibition potentiates drugs targeting DNA topoisomerase II2016
Professor Graham Jackson
Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial2016
Professor Graham Jackson
Dr Richard Quinton
Testosterone treatment is not associated with increased risk of adverse cardiovascular events: results from the Registry of Hypogonadism in Men (RHYME)2016
Professor Graham Jackson
The NCRI Myeloma XI trial for newly diagnosed symptomatic multiple myeloma (NDMM); second primary malignancy (SPM) incidence when lenalidomide is used as an induction and maintenance treatment option2016
Professor Graham Jackson
The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in Myeloma2016
Dr Laura Jardine
Dr Venetia Bigley
Dr Kim Pearce
Dr Alison Dickinson
Professor Graham Jackson
et al.
A comparative study of reduced dose alemtuzumab in matched unrelated donor and related donor reduced intensity transplants2015
Professor Graham Jackson
A molecular diagnostic approach able to detect the recurrent genetic prognostic factors typical of presenting myeloma2015
Professor Graham Jackson
APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma2015
Professor Graham Jackson
Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations2015
Dr Nicola Sunter
Dr Helen Marr
Dr Andrew Hall
Dr Tryfonia Mainou-Fowler
Professor Graham Jackson
et al.
Common variation at 12q24.13 (OAS3) influences chronic lymphocytic leukemia risk2015
Catriona Manville
Kayleigh Smith
Dr Zbyslaw Sondka
Holly Rance
Dr Ian Cowell
et al.
Genome-wide ChIP-seq analysis of human TOP2B occupancy in MCF7 breast cancer epithelial cells2015
Dr Gail Jones
Professor Graham Jackson
Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology2015
Professor Graham Jackson
Implementation of genome-wide complex trait analysis to quantify the heritability in multiple myeloma2015
Professor Graham Jackson
Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction2015
Professor Graham Jackson
Molecular Subgroups of Hyperdiploidy and Their Prognostic Relevance - an Analysis of 1,036 Myeloma Trial Patients2015
Professor Graham Jackson
Molecular Subtyping and Risk Stratification for the Classification of Myeloma2015
Dr Aneta Mikulasova
Professor Graham Jackson
Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma2015
Professor Graham Jackson
Myeloma XI Trial for Newly Diagnosed Multiple Myeloma (NDMM); A Report of Second Primary Malignancy (SPM) Rates and the Importance of Review of Reported Cases2015
Dr Kim Pearce
Jean Norden
Professor Matthew Collin
Professor Graham Jackson
Dr Udo Holtick
et al.
Predicting survival using clinical risk score and non-HLA immunogenetics2015
Professor Graham Jackson
Quadruplet Vs Sequential Triplet Induction Therapy Approaches to Maximise Response for Newly Diagnosed, Transplant Eligible, Myeloma Patients2015
Professor Graham Jackson
Spatiotemporal Analysis of Intraclonal Heterogeneity in Multiple Myeloma: Unravelling the Impact of Treatment and the Propagating Capacity of Subclones Using Whole Exome Sequencing2015
Professor Graham Jackson
Specific Identification of High Risk Disease Using Molecular Profiling By Mymap (Myeloma MLPA and translocation PCR) of 1,036 Cases2015
Professor Graham Jackson
The British Society for Haematology: 'What have the Romans ever done for us?'2015
Professor Graham Jackson
The Quadruplet Combination of Carfilzomib, Cyclophosphamide, Lenalidomide, and Dexamethasone is Safe and Well Tolerated as Induction Therapy for Newly Diagnosed, Transplant Eligible, Myeloma Patients2015
Professor Graham Jackson
Time to redefine Myeloma2015
Dr Nicola Sunter
Dr Andrew Hall
Dr Tryfonia Mainou-Fowler
Professor Graham Jackson
Professor James Allan
et al.
A genome-wide association study identifies multiple susceptibility loci for chronic lymphocytic leukemia2014
Professor Graham Jackson
A retrospective multi-centre study of the effects of allogeneic haematopoietic SCT on pulmonary function2014
Professor Graham Jackson
Apobec Family Mutational Signatures Are Associated with Poor Prognosis Translocations in Multiple Myeloma2014
Professor Graham Jackson
Autologous stem cell transplantation in severe treatment-resistant Crohn's disease: long-term follow-up of UK patients treated on compassionate basis2014
Professor Graham Jackson
High Resolution Genome Wide DNA Methylation Analysis in a Large Trial Group Reveals a Novel Epigenetically Defined Subgroup of Myeloma Patients Characterized By Developmental Gene Hypermethylation2014
Professor Graham Jackson
High Throughput Genetic Profiling Using a Robust All-Molecular Diagnostic Approach Is Feasible to Specifically Identify a High Risk Group of Myeloma Patients2014
Professor Graham Jackson
Minimal Residual Disease: What Are the Minimum Requirements? Reply2014
Professor Graham Jackson
Mutational Patterns and Copy Number Changes at Diagnosis Are a Powerful Tool to Predict Outcome: Result of the Sequencing Study of 463 Newly Diagnosed Myeloma Trial Patients2014
Professor Graham Jackson
Optimising the use of plerixafor in stem cell mobilisation2014
Professor Graham Jackson
Optimizing induction and pretransplant consolidation for myeloma: Results of Myeloma XI, a phase III trial comparing different IMiDs2014
Professor Graham Jackson
Osteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma: Medical Research Council Myeloma IX Study results2014
Professor Graham Jackson
Psychosocial supportive care services for haematopoietic stem cell transplant patients; a service evaluation of three UK transplant centres2014
Professor Graham Jackson
Rapid, Robust and Accessible Molecular Profiling of Biologically and Clinically Relevant Copy Number Alterations in Multiple Myeloma from Small Amounts of Tumor DNA2014
Professor Graham Jackson
Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome2014
Dr Laura Jardine
Dr Kile Green
Professor Graham Jackson
Professor Matthew Collin
Synergy of Unrelated Donor and Full Intensity Conditioning Breaks the Control of Graft Versus Host Disease By Alemtuzumab2014
Professor Graham Jackson
Dr Venetia Bigley
Professor Matthew Collin
T cell depleted reduced intensity transplantation is effective for patients with GATA2 mutation and severe infections or respiratory compromise2014
Professor Graham Jackson
The Extent of Intra-Clonal Genetic Diversity within the Myeloma Clone Is a Predictive Biomarker of Progression and Outcome after Treatment2014
Professor Graham Jackson
The Spectrum of Epigenetic Mutations in Myeloma and Their Clinical Impact2014
Professor Graham Jackson
The UK and Ireland Perspective: European Post-Approval Safety Study (Pass) in Relapsed/Refractory Multiple Myeloma Patients Treated with Lenalidomide, Bortezomib, and Thalidomide2014
Professor Graham Jackson
Biologically defined risk groups can be used to define the impact of thalidomide maintenance therapy in newly diagnosed multiple myeloma2013
Professor Graham Jackson
Professor Julie Irving
Professor James Allan
Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma risk2013
Dr Kile Green
Dr Laura Jardine
Dr Kim Pearce
Dr Venetia Bigley
Professor Graham Jackson
et al.
Defining The Optimal Dose Of Alemtuzumab In Unrelated Donor Reduced Intensity Allografts: A UK Retrospective Study2013
Dr Christopher Bacon
Sarah Wilkinson
Dr Gavin Spickett
Dr Helen Lucraft
Professor Graham Jackson
et al.
Epstein-Barr virus-independent diffuse large B-cell lymphoma in DNA ligase 4 deficiency2013
Professor Graham Jackson
Long-term Follow-up of MRC Myeloma IX Trial: Survival Outcomes with Bisphosphonate and Thalidomide Treatment2013
Professor Graham Jackson
Management of cytomegalovirus infection in haemopoietic stem cell transplantation2013
Professor Graham Jackson
Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma: Impact on Outcome in the Medical Research Council Myeloma IX Study2013
Professor Graham Jackson
Response and biological subtype of myeloma are independent prognostic factors and combine to define outcome after high-dose therapy2013
Professor Graham Jackson
The CCND1 c.870G > A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma2013
Dr Sarah Fordham
Dr Victoria Forster
Professor Graham Jackson
Dr Simon Bomken
Professor James Allan
et al.
A functional variant in the core promoter of the CD95 cell death receptor gene predicts prognosis in acute promyelocytic leukemia2012
Professor Graham Jackson
A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial2012
Professor Graham Jackson
Allogeneic Stem Cell Transplantation for Myelofibrosis in 20122012
Professor Graham Jackson
Professor Christine Harrison FRCPath FMedSci
Professor Simon Bailey
Burkitt's lymphoma2012
Professor Graham Jackson
Common variation at 3p22.1 and 7p15.3 influences multiple myeloma risk2012
Professor Graham Jackson
Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results2012
Professor Graham Jackson
Diagnosis and management of chronic graft-versus-host disease2012
Professor Graham Jackson
Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial2012
Dr Mario Abinun
Professor Graham Jackson
Haematopoietic stem cell transplantation (HSCT) in severe autoimmune diseases: analysis of UK outcomes from the British Society of Blood and Marrow Transplantation (BSBMT) data registry 1997-20092012
Dr Catherine Stroud
Professor Matthew Collin
Professor Graham Jackson
Dr Terence Flood
Dr John Mansfield
et al.
Idiopathic colitis following haematopoietic stem cell transplantation for chronic granulomatous disease: Three cases at a national centre2012
Professor Graham Jackson
Mobilized Peripheral Blood Stem Cells Compared with Bone Marrow as the Stem Cell Source for Unrelated Donor Allogeneic Transplantation with Reduced-Intensity Conditioning in Patients with Acute Myeloid Leukemia in Complete Remission: An Analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation2012
Dr Ian Cowell
Dr Zbyslaw Sondka
Kayleigh Smith
Ka Lee
Catriona Manville
et al.
Model for MLL translocations in therapy-related leukemia involving topoisomerase IIβ-mediated DNA strand breaks and gene proximity2012
Dr Kay Padget
Hannah Curtis
Dr Ian Cowell
Dr Zbyslaw Sondka
Dr Nick Morris
et al.
MRE11 facilitates the removal of human topoisomerase II complexes from genomic DNA2012
Professor Graham Jackson
Organ-specific management and supportive care in chronic graft-versus-host disease2012
Dr Jonathan Lane
Dr Mary Slatter
Professor Sophie Hambleton
Dr Terence Flood
Professor Andrew Cant
et al.
Outcome of haematopoietic stem cell transplantation in patients with chronic granulomatous disease at a national centre2012
Dr Katherine Sturgess
Dr Mary Slatter
Dr Venetia Bigley
Dr Rachel Dickinson
Professor Muzlifah Haniffa
et al.
Reduced-intensity haematopoietic stem cell transplant rescues immune function and corrects pulmonary alveolar proteinosis in DCML deficiency/GATA 2 mutation2012
Professor Graham Jackson
Sequential Immunomodulatory Drug (IMiD) and Proteosome Inhibitor Therapy Improves Response Rates in Newly Diagnosed Multiple Myeloma: Preliminary Results From the Myeloma XI Trial2012
Professor Graham Jackson
The Impact of Thalidomide Maintenance Therapy Varies Dependent Upon Biological Risk Grouping2012
Professor Graham Jackson
A Gene Expression-Based Predictor for Myeloma Patients at High Risk of Developing Bone Disease on Bisphosphonate Treatment2011
Michael Batey
Dr Yan Zhao
Dr Helen Maitland
Professor Hing Leung
Dr Andrew Hall
et al.
Comparative pre-clinical evaluation of receptor tyrosine kinase inhibitors for the treatment of multiple myeloma2011
Professor Graham Jackson
Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation2011
Dr Venetia Bigley
Professor Muzlifah Haniffa
Dr Xiao Wang
Dr Rachel Dickinson
Dr Naomi McGovern
et al.
Dendritic cell, monocyte, B and NK lymphoid deficiency: a novel but potentially fatal haematological disorder curable with haematopoietic stem cell transplantation2011
Professor Graham Jackson
Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial2011
Dr Faye Cooles
Professor Graham Jackson
Professor John Isaacs
Epstein-Barr virus-driven lymphoproliferative disorder post-CAMPATH-1H (alemtuzumab) in refractory polymyositis2011
Professor Graham Jackson
Heterogeneity in the Prognostic Significance of 12p Deletion and Chromosome 5 Amplification in Multiple Myeloma2011
Professor Graham Jackson
Mapping of Chromosome 1p Deletions in Myeloma Identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as Being Genes in Regions Associated with Adverse Survival2011
Professor Graham Jackson
MRC Myeloma IX, 6 Year Median Follow-up (FU) Highlights the Importance of Long-Term FU in Myeloma Clinical Trials and Differential Effects of Thalidomide in High- and Low-Risk Disease2011
Jean Norden
Professor Matthew Collin
Professor Graham Jackson
Professor Anne Dickinson
Prognostic Significance of Interleukin-7 Receptor-alpha Gene Polymorphisms in Allogeneic Stem-Cell Transplantation: A Confirmatory Study2011
Dr Katherine Sturgess
Dr Mary Slatter
Dr Venetia Bigley
Professor Muzlifah Haniffa
Dr Xiao Wang
et al.
Reduced Intensity Hematopoietic Stem Cell Transplant Rescues Immune Function and Corrects Pulmonary Alveolar Proteinosis in DCML Deficiency/GATA 2 Mutation2011
Professor Graham Jackson
Results of the Medical Research Council (MRC) Myeloma IX study: Effects of zoledronic acid (ZOL) on overall survival (OS) in patients with multiple myeloma (MM)2011
Professor Graham Jackson
The Interaction of Response and FISH-Based Risk Stratification to Better Define Clinical Outcome in Myeloma2011
Dr Shaheda Ahmed
Dr Xiao Wang
Professor Graham Jackson
Professor Anne Dickinson
The Involvement of Epithelial Fas in a Human Model of Graft Versus Host Disease2011
Professor Graham Jackson
The role of in vivo T-cell depletion on reduced-intensity conditioning allogeneic stem cell transplantation from HLA-identical siblings in patients with follicular lymphoma2011
Dr Ebtesam El-Gezawy
Professor Graham Jackson
Professor Anne Dickinson
A biomarker panel associated with acute and chronic graft-versus-host disease2010
Dr Nicola Sunter
Professor Graham Jackson
Dr Simon Bomken
Professor James Allan
A Functional Polymorphism In the CD95 Cell Death Receptor Associated with Prognosis In Acute Promyelocytic Leukemia2010
Professor Graham Jackson
Dr Simon Bomken
Professor James Allan
A Functional Polymorphism In the CD95 Cell Death Receptor Associated with Prognosis In Acute Promyelocytic Leukemia2010
Professor Graham Jackson
Dr Nicola Sunter
Dr Andrew Hall
Professor Julie Irving
Professor James Allan
et al.
A polymorphism in the 3' UTR of IRF4 linked to susceptibility and pathogenesis in chronic lymphocytic leukaemia and Hodgkin lymphoma has limited impact in multiple myeloma2010
Dr Wei Cope
Dr Laura Jardine
Dr Venetia Bigley
Sarah Pagan
Brie Turner
et al.
A retrospective study of alemtuzumab level, t-cell chimerism and graft-versus-host disease using intermediate dose alemtuzumab for matched related and matched unrelated reduced-intensity transplantation2010
Professor Graham Jackson
Professor Matthew Collin
Jean Norden
Clinical and genetic risk assessment for overall survival in haematopoietic stem cell transplantation2010
Dr Nicola Sunter
Dr Andrew Hall
Dr Tryfonia Mainou-Fowler
Professor Graham Jackson
Professor James Allan
et al.
Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk2010
Dr Faye Cooles
Professor Graham Jackson
Professor John Isaacs
EBV driven lymphoproliferative disease following alemtuzumab (CAMPATH-1H) in refractory polymyositis2010
Dr John Byrne
Professor Graham Jackson
First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial2010
Professor Graham Jackson
Optimising Bone Disease In Myeloma, Zoledronic Acid Plus Thalidomide Combinations Improves Survival and Bone Endpoints Results of the MRC Myeloma IX Trial2010
Professor Graham Jackson
Thalidomide maintenance significantly improves progression free (PFS) but not overall survival (OS) of myeloma patients, with PFS benerts in favourable fish subgroups only: MRC myeloma IX results2010
Professor Graham Jackson
Thalidomide Maintenance Significantly Improves Progression Free Survival (PFS) and Overall Survival (OS) of Myeloma Patients When Effective Relapse Treatments Are Used MRC Myeloma IX Results2010
Professor Stephen Proctor
Dr Anne Lennard
Professor Graham Jackson
Dr Jennifer Wilkinson
Dr Michal Sieniawski
et al.
The role of an all-oral chemotherapy containing lomustine (CCNU) in advanced,fs progressive Hodgkin lymphoma: a patient-friendly palliative option which can result in long-term disease control2010
Professor James Allan
Dr Nicola Sunter
Dr Andrew Hall
Dr Christopher Bacon
Jonathan Pointon
et al.
Variant IRF4/MUM1 associates with CD38 status and treatment-free survival in chronic lymphocytic leukaemia2010
Professor Graham Jackson
Zoledronic acid (ZOL) prolongs time to first skeletal-related event (SRE) and survival versus clodronate in newly diagnosed multiple myeloma (MM): MRC myeloma IX trail results2010
Professor Graham Jackson
Zoledronic acid (ZOL) significantly increases progression-free survival (FPS) versus clodronate and may improve response rates in newly diagnosed multiple myeloma (MM): MRC myeloma IX trail results2010
Professor Graham Jackson
Zoledronic acid (ZOL) significantly reduces skeletal-related events (SRES) versus clodronate (CLO) in patients (PTS) with multiple myeloma (MM): Results of the medical research council (MRC) Myeloma IX Study2010
Dr Venetia Bigley
Sarah Pagan
Brie Turner
Professor Graham Jackson
Professor Anne Dickinson
et al.
A Retrospective Study of Alemtuzumab Level, T Cell Chimerism and Graft Versus Host Disease Using Intermediate Dose Alemtuzumab for Matched Related and Matched Unrelated Reduced Intensity Transplantation.2009
Professor Anne Dickinson
Dr Kim Pearce
Professor Graham Jackson
Professor Matthew Collin
Jean Norden
et al.
Clinical and Genetic Risk Assessment for Overall Survival in Haematopoietic Stem Cell Transplantation (HSCT)2009
Anna Kuzyk-Czucha
Professor Graham Jackson
Donor HSP70-hom gene polymorphism contributes to the development of chronic GvHD after allogeneic hematopoietic stem cell transplantation2009
Professor Anne Dickinson
Professor Graham Jackson
G to C transition at position-173 of MIF gene of the recipient is associated with reduced relapse rates after allogeneic stem cell transplantation2009
Professor Graham Jackson
Mobilized Peripheral Blood Stem Cells (PBSC) Compared with Bone Marrow (BM) as the Stem Cell Source for Unrelated Donor Allogeneic Transplantation with Reduced Intensity Conditioning (RIC-alloSCT) in Patients with Acute Myeloid Leukemia (AML) in Complete Remission (CR): a Retrospective Analysis From the ALWP of EBMT2009
Dr Xiao Wang
Dr Udo Holtick
Professor Matthew Collin
Professor Graham Jackson
Professor Catharien Hilkens
et al.
Regulatory T-Cell Suppression of CD8+ T-Cell-Mediated Graft-Versus-Host Reaction Requires Their Presence During Priming2009
Professor Graham Jackson
The Addition of Thalidomide to the Induction Treatment of Newly Presenting Myeloma Patients Increases the CR Rate Which Is Likely to Translate Into Improved PFS and OS2009
Professor Graham Jackson
The Role of In Vivo T-Cell Depletion On Reduced Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation From HLA-Identical Siblings in Patients with Follicular Lymphoma: An European Blood and Marrow Transplantation Study2009
Dr Laura Jones
Dr Stephen Hodges
Dr Terence Flood
Dr Gavin Spickett
Professor Graham Jackson
et al.
Unrelated donor and HLA-identical sibling haematopoietic stem cell transplantation cure chronic granulomatous disease with good long-term outcome and growth2009
Jane Harrold
Jean Norden
Professor Graham Jackson
Professor Anne Dickinson
IL13 +2044 (Arg130Gln) Associates with Acute and Chronic Graft-Versus-Host Disease Following Haematopoietic Stem Cell Transplantation2008
Professor James Allan
Dr Nicola Sunter
Dr Andrew Hall
Dr Tryfonia Mainou-Fowler
Professor Graham Jackson
et al.
A Common Genetic Variant in the 3'UTR of IRF4/MUM1 Associates with Risk of Disease and Poor Prognosis in Chronic Lymphocytic Leukaemia2008
Dr Nicola Sunter
Dr Andrew Hall
Dr Tryfonia Mainou-Fowler
Professor Graham Jackson
Professor James Allan
et al.
A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia2008
Dr Elaine Willmore
Dr sarah Johnson
Dr Tryfonia Mainou-Fowler
Professor Graham Jackson
Dr Celine Cano
et al.
DNA-dependent protein kinase is a therapeutic target and an indicator of poor prognosis in B-cell chronic lymphocytic leukemia2008
Dr Elaine Willmore
Dr sarah Johnson
Clark Crawford
Dr Tryfonia Mainou-Fowler
Professor Graham Jackson
et al.
DNA-Dependent Protein Kinase Is a Therapeutic Target in Poor Prognosis B-Cell Chronic Lymphocytic Leukemia2008
Professor Anne Dickinson
Professor Graham Jackson
G to C transition at position -173 of MIF gene of the recipient is associated with improved outcome after allogeneic stem cell transplantation2008
Professor Graham Jackson
Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping2008
Dr Terence Flood
Dr Gavin Spickett
Professor Graham Jackson
Professor Matthew Collin
Dr Mario Abinun
et al.
Haematopoeitic stem cell transplantation for chronic granulomatous disease - a single-centre experience2008
Michael Batey
Dr Helen Maitland
Professor Hing Leung
Dr Andrew Hall
Professor Graham Jackson
et al.
In vitro activity of the multi targeted receptor tyrosine kinase inhibitor sunitinib against multiple myeloma cell lines is not predictive of in vivo xenograft response2008
Professor Graham Jackson
Maintenance Thalidomide May Improve Progression Free but Not Overall Survival; Results from the Myeloma IX Maintenance Randomisation2008
Professor Graham Jackson
Professor James Allan
Polymorphic MLH1 and risk of cancer after methylating chemotherapy for Hodgkin lymphoma2008
Professor Graham Jackson
Position statement on the use of bortezomib in multiple myeloma2008
Jane Harrold
Dr Elizabeth Leitch
Jean Norden
Dr Xiao Wang
Professor Graham Jackson
et al.
Role of interleukin-13 in predicting graft-versus-host disease; functional and genotyping studies2008
Dr Michal Sieniawski
Dr Tryfonia Mainou-Fowler
Dr Jennifer Wilkinson
Dr John Davison
Professor Graham Jackson
et al.
The effect of Diffuse Large B-Cell Lymphoma (DLBCL) treatment regimens on survival: a prospective cohort study [Poster]2008
Professor Anne Dickinson
Professor Graham Jackson
The role of genetic variants of NOD2/CARD15, a receptor of the innate immune system, in GvHD and complications following related and unrelated donor haematopoietic stem cell transplantation2008
Professor Graham Jackson
Defining complete response in multiple myeloma: Role of the serum free light chain assay and multiparameter flow cytometry2007
Professor Graham Jackson
High loading dose AmBisome® is efficacious and well tolerated in the management of invasive fungal infection in hematology patients2007
Professor Graham Jackson
Response by SFLC and marrow flow cytometry in MRC myeloma IX2007
Professor Graham Jackson
Thalidomide maintenance following high-dose therapy in multiple myeloma: a UK myeloma forum phase 2 study2007
Dr Sara Brown
Professor Graham Jackson
Professor Nick Reynolds
Dr Clifford Lawrence
Chronic cutaneous graft-versus-host disease associated with multiple cutaneous squamous cell carcinomas2006
Dr David Milligan
Professor Graham Jackson
Dr Archibold Hunter
Dr Roger Pearce
De-escalation of the alemtuzumab dose prior to nonmyeloablative HLA-identical sibling transplantation: Crucial role of timing2006
Professor Anne Dickinson
Professor Graham Jackson
NOD2/CARD15 mutations associate with transplant-related mortality and GvHD) in HLA-identical sibling transplants: Detailed analysis of single SNPs in 209 recipient/donor pairs2006
Professor Graham Jackson
Phase III trial of oral ibandronate versus intravenous zoledronic acid in multiple myeloma: Study design2006
Professor Anne Dickinson
Professor Graham Jackson
Prognostic significance of NOD2/CARD15 polymorphisms in allogeneic HSCT from unrelated donors2006
Dr Elaine Willmore
Professor Graham Jackson
Dr Tryfonia Mainou-Fowler
Professor Caroline Austin
Professor barbara Durkacz
et al.
Sensitisation of B-CLL cells to chlorambucil and fludarabine via inhibition of the DNA damage sensor proteins, DNA-PK and ATM2006
Dr Xiao Wang
Professor Matthew Collin
Professor Graham Jackson
Professor Anne Dickinson
Skin Explant Model of Human Graft-Versus-Host Disease: Prediction of Clinical Outcome and Correlation with Biological Risk Factors2006
Dr Elaine Willmore
Dr Tryfonia Mainou-Fowler
Professor Graham Jackson
Professor barbara Durkacz
Targeting DNA-PK and ATM increases sensitivity to chlorambucil and fludarabine in chemoresistant and p53-defective B-CLL cells2006
Dr Penelope Taylor
Dr Brian Angus
Professor Graham Jackson
Dr Helen Lucraft
Professor Stephen Proctor
et al.
The addition of oral idarubicin to a chlorambucil/dexamethasone combination has a significant impact on time to treatment failure but none on overall survival in patients with low grade non-Hodgkin's lymphoma: Results of the Scotland and Newcastle Lymphoma Group randomized NHL VIII trial2006
Professor Matthew Collin
Professor Graham Jackson
Dr Jennifer Cavet
Dr Peter Middleton
Professor Anne Dickinson
et al.
The fate of human Langerhans cells in hematopoietic stem cell transplantation2006
Dr Xiao Wang
Professor Graham Jackson
Professor Anne Dickinson
An in vitro test of steroid responsiveness using a modified human skin explant model for graft-versus-host disease2005
Professor Graham Jackson
Beth Gibson
An open-label study of high-dose liposomal amphotericin B (AmBisome (R)) in the treatment of proven and probable invasive fungal infections2005
Professor Graham Jackson
Bortezomib, a novel proteasome inhibitor, in the treatment of hematologic malignancies2005
Dr Trevor Booth
Dr Peter Middleton
Professor Graham Jackson
Dr Jennifer Cavet
Dr Xiao Wang
et al.
Human langerhans cells in transplantation: Recipient cells survive conditioning but donor cells predominate at day 1002005
Professor Graham Jackson
Dr Jennifer Cavet
Dr Trevor Booth
Dr Peter Middleton
Dr Xiao Wang
et al.
Human Langerhans cells in transplantation: Recipient cells survive conditioning but donor cells predominate at day 1002005
Dr Mark Velangi
Professor Graham Jackson
Less than half of patients aged 65 years or under with myeloma proceed to transplantation: results of a two region population-based survey2005
Professor Graham Jackson
Renal safety of ibandronate2005
Professor Graham Jackson
Response to Goodman et al.: Amyloidosis, not myeloma2005
Professor Graham Jackson
Safety and compliance of intravenous and oral dosing regimens2005
Professor Graham Jackson
Safety issues influence choice2005
Professor Graham Jackson
Dr Jennifer Cavet
Professor Anne Dickinson
The fate of human Langerhans cells in hematopoietic stem cell transplantation2005
Professor Graham Jackson
The issue of renal safety of zoledronic acid from a nephrologist's point of view2005
Dr Elaine Willmore
Dr Nicola Sunter
Dr Michael Tilby
Professor Graham Jackson
Professor Caroline Austin
et al.
A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia2004
Dr Mark Velangi
Elizabeth Matheson
Dr Penelope Taylor
Professor Graham Jackson
Dr Andrew Hall
et al.
BRAF gene is not mutated in mismatch repair-proficient or -deficient plasma cell dyscrasias 2004
Dr Mark Velangi
Elizabeth Matheson
Professor Graham Jackson
Dr Penelope Taylor
Dr Andrew Hall
et al.
DNA mismatch repair pathway defects in the pathogenesis and evolution of myeloma2004
Edward Leung
Dr Brian Shenton
Professor Graham Jackson
Professor Kate Gould
David Talbot
et al.
Dynamic EBV gene loads in renal, hepatic, and cardiothoracic transplant recipients as determined by real-time PCR light cycler2004
Professor Graham Jackson
Newly diagnosed myeloma pateints are at risk of venous thrombotic events - High risk patients need to be identified and recieve thromboprophylaxis: The MRC experience2004
Professor Anne Dickinson
Professor Graham Jackson
NOD2/CARD15 mutations associate with transplant related mortality and GvHD in HLA-identical sibling transplants: Detailed analysis of single SNPs in 211 recipient/donor pairs2004
Professor Graham Jackson
Dr Mark Velangi
Only a minority of age eligible patients with myeloma undergo treatment with autologous transplantation. A population based study of the contributory factors. A combined survey on behalf of The Northern Ireland Regional Haematology Group (NIRHG) and The Newcastle Regional Haematology Group (NRHG)2004
Professor Graham Jackson
Dr Mark Velangi
Only a minority of myeloma patients aged under 65 years receive high-dose therapy with autologous transplantation2004
Professor Graham Jackson
Results of an open-label study of high-dose liposomal amphotericin B (AmBisome) in the treatment of confirmed fungal infections in high-risk patients2004
Professor Graham Jackson
Use of fludarabine in the treatment of acute myeloid leukemia2004
Eileen Leung
Dr Brian Shenton
Katherine Green
Katherine Gould
Professor Graham Jackson
et al.
Changes in EBV gene load in renal transplant recipients2003
Dr Theresa Wardell
Professor Patrick Chinnery
Dr Gillian Borthwick
Professor Robert Taylor
Professor Graham Jackson
et al.
Changes in the human mitochondrial genome after treatment of malignant disease2003
Dr Theresa Wardell
Elizabeth Ferguson
Professor Patrick Chinnery
Dr Gillian Borthwick
Professor Robert Taylor
et al.
Changes in the human mitochondrial genome after treatment of malignant disease2003
Dr Peter Middleton
Professor Anne Dickinson
Mandy Jarvis
Dr Jennifer Cavet
Dr Hannah Cullup
et al.
Clinical and genotypic risk factors for GvHD are modulated by prophylaxis: A multicentre cohort study of HLA matched sib-allo BMT2003
Dr Mark Velangi
Professor Graham Jackson
Dr Penelope Taylor
Dr Andrew Hall
Professor Julie Irving
et al.
DNA mismatch repair pathway defects in the pathogenesis and evolution of myeloma2003
Professor Graham Jackson
Human herpesvirus 6 encephalitis following flag chemotherapy2003
Dr Peter Middleton
Jean Norden
Dr Hannah Cullup
Dr Jennifer Cavet
Professor Graham Jackson
et al.
Oestrogen receptor α gene polymorphism associates with occurrence of graft-versus-host disease and reduced survival in HLA-matched sib-allo BMT2003
Dr Hannah Cullup
Professor Anne Dickinson
Dr Jennifer Cavet
Professor Graham Jackson
Dr Peter Middleton
et al.
Polymorphisms of interleukin-1α constitute independent risk factors for chronic graft-versus-host disease after allogeneic bone marrow transplantation2003
Professor Stephen Proctor
Professor Graham Jackson
Dr Anne Lennard
Dr Brian Angus
Dr Katrina Wood
et al.
Strategic approach to the management of Hodgkin's disease incorporating salvage therapy with high-dose ifosfamide, etoposide and epirubicin: a Northern Region Lymphoma Group study (UK)2003
Dr Gail Stark
Professor Anne Dickinson
Professor Graham Jackson
Dr Penelope Taylor
Professor Stephen Proctor
et al.
Tumour necrosis factor receptor type II 196M/R genotype correlates with circulating soluble receptor levels in normal subjects and with graft-versus-host disease after sibling allogeneic bone marrow transplantation2003
Professor Stephen Proctor
Dr Brian Angus
Professor Graham Jackson
Dr Anne Lennard
Dr Penelope Taylor
et al.
A population-based study of intensive multi-agent chemotherapy with or without autotransplant for the highest risk Hodgkin's disease patients identified by the Scotland and Newcastle Lymphoma Group (SNLG) prognostic index. A Scotland and Newcastle Lymphoma Group study (SNLG HD III)2002
Dr Mark Velangi
Dr Michael Reid
Dr Nicholas Bown
Professor Graham Jackson
Professor Stephen Proctor
et al.
Acute lymphoblastic leukaemia of the L3 subtype in adults in the Northern health region of England 1983-992002
Professor Graham Jackson
Dr Penelope Taylor
Acute myeloid leukaemia - Optimising treatment in elderly patients2002
Dr Xiao Wang
Professor Graham Jackson
Professor Anne Dickinson
Interleukin-10 modulation of alloreactivity and graft-versus-host reactions2002
Mandy Jarvis
Professor Anne Dickinson
Professor Graham Jackson
Dr Xiao Wang
The detection of apoptosis in a human in vitro skin explant assay for graft versus host reactions2002
Eileen Leung
Dr Brian Shenton
Professor Graham Jackson
Professor Kate Gould
David Talbot
et al.
Use of real-time PCR to measure Epstein-Barr virus genomes in whole blood2002
Dr Peter Middleton
Dr Hannah Cullup
Professor Anne Dickinson
Jean Norden
Professor Graham Jackson
et al.
Vitamin D receptor gene polymorphism associates with graft-versus-host disease and survival in HLA-matched sibling allogeneic bone marrow transplantation2002
Professor Graham Jackson
A multicentre, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blasts in transformation2001
Professor Graham Jackson
Dr David Milligan
Accelerated telomere shortening following allogeneic transplantation is independent of the cell source and occurs within the first year post transplant2001
Dr Hannah Cullup
Professor Anne Dickinson
Professor Graham Jackson
Dr Peter Middleton
Donor interleukin 1 receptor antagonist genotype associated with acute graft-versus-host disease in human leucocyte antigen-matched sibling allogeneic transplants2001
Dr Nicholas Bown
Dr Michael Reid
Dr Peter Hamilton
Professor Graham Jackson
Dr Penelope Taylor
et al.
Erythroleukaemia in the north of England: a population based study2001
Professor Graham Jackson
Dr Xiao Wang
Professor Anne Dickinson
Histological correlation between different centers using the skin explant model to predict graft-versus-host disease following bone marrow transplantation2001
Professor Anne Dickinson
Jean Norden
Dr Penelope Taylor
Professor Graham Jackson
Dr Peter Middleton
et al.
Interferon-gamma and interleukin-6 gene polymorphisms associate with graft-versus-host disease in HLA-matched sibling bone marrow transplantation2001
Professor Graham Jackson
Professor Stephen Proctor
Massive haemolysis in a group A recipient of a group O peripheral blood stem cell allogeneic transplant2001
Dr Xiao Wang
Professor Anne Dickinson
Professor Graham Jackson
Minor histocompatibility antigen specific CTLs and in situ skin graft versus host reactions2001
Professor Graham Jackson
Filippo Di Franco
David Talbot
Outcome of PTLD in renal and liver allograft recipients2001
Dr Anne Lennard
Professor Graham Jackson
Stem cell transplantation2001
Professor Julie Irving
Dr Penelope Taylor
Professor Graham Jackson
Dr Andrew Hall
The presence of mismatch repair defects in plasma cell dyscrasias2001
Dr Sally Coulthard
Dr Christopher Howell
Lynne Minto
Dr Peter Middleton
Professor Graham Jackson
et al.
A comparison of molecular and enzyme-based assays for the detection of thiopurine methyltransferase mutations2000
Dr Brian Angus
Dr Fergus Jack
Professor Graham Jackson
Professor Stephen Proctor
Dr Penelope Taylor
et al.
Improved estimation of tumour burden leads to better prognostic discrimination in classical hodgkin's disease in adults2000
Dr Anne Lennard
Professor Graham Jackson
Science, medicine, and the future - Stem cell transplantation2000
Dr Janet McComb
Dr Patrick Kesteven
Emerita Professor Sally Marshall
Professor Graham Jackson
Endothelial dysfunction, disordered coagulation and fibrinolysis in patients with type 2 diabetes and microalbuminuria1999
Dr Xiao Wang
Kerry-Ann Oliver
Professor Anne Dickinson
Professor Graham Jackson
Increased sensitivity of the cord blood alloresponse to cyclosporin1999
Dr Peter Middleton
Jean Norden
Dr Jennifer Cavet
Professor Graham Jackson
Professor Anne Dickinson
et al.
Interleukin-6 gene polymorphism associated with absence of severe graft-versus-host-disease in allogeneic BMT: A possible genetic protection factor.1999
Professor Anne Dickinson
Professor Graham Jackson
Dr Penelope Taylor
Professor Stephen Proctor
Use of a skin explant model for predicting GVHD in HLA-matched bone marrow transplants - effect of GVHD prophylaxis1999
Dr Peter Middleton
Dr Penelope Taylor
Professor Graham Jackson
Professor Stephen Proctor
Professor Anne Dickinson
et al.
Cytokine gene polymorphisms associating with severe acute graft-versus-host disease in HLA-identical sibling transplants1998
Professor Graham Jackson
Dr Penelope Taylor
Dr Anne Lennard
Professor Anne Dickinson
Dr Peter Hamilton
et al.
Single centre experience of allogeneic bone marrow transplantation with GvHD prophylaxis based on cyclosporin alone: March 1983 June 19971998
Professor Graham Jackson
Dr Philip Taylor
Dr David Goff
Dr Anne Lennard
Dr Brian Angus
et al.
High dose ifosfamide in combination with etoposide and epirubicin in the treatment of relapsed/refactory Hodgkin's disease: A report on toxicity and efficacy.1997
Professor Graham Jackson
Dr Penelope Taylor
Dr Peter Hamilton
Professor Stephen Proctor
The use of an all oral chemotherapy (idarubicin and etoposide) in the treatment of acute myeloid leukaemia in the elderly: a report of toxicity and efficacy1997
Dr Andrew Hall
Professor Graham Jackson
Congenital deficiency of thiopurine methyltransferase as a cause of pancytopenia in patients treated with azathioprine1996
Professor Julie Irving
Professor Stephen Proctor
Professor Graham Jackson
Basophilia, t(15;17) translocation and atypical AML1995
Professor Graham Jackson
Dr Anne Lennard
Dr Peter Hamilton
Professor Stephen Proctor
Low frequency of myelodysplasia after autologous bone marrow transplantation1995
Professor Graham Jackson
Dr Penelope Taylor
Dr Anne Lennard
Professor Stephen Proctor
Autologous bone marrow transplantation in acute lymphoblastic leukaemia1994
Professor Graham Jackson
Dr Anne Lennard
Dr Penelope Taylor
Dr Peter Carey
Dr Brian Angus
et al.
Autologous bone marrow transplantation in poor-risk high-grade non-Hodgkin's lymphoma in first complete remission1994
Professor Anne Dickinson
Dr Peter Hamilton
Dr Penelope Taylor
Professor Graham Jackson
Professor Stephen Proctor
et al.
Cytokine involvement in predicting clinical graft-versus-host disease in allogeneic bone marrow transplant recipients1994
Professor Anne Dickinson
Professor Graham Jackson
Professor Stephen Proctor
Monoclonal anti-TNF-α suppresses graft vs host disease reactions in an in vitro human skin model1994
Professor Graham Jackson
Dr Anne Lennard
Dr Penelope Taylor
Professor Stephen Proctor
Rapid onset of chronic granulocytic leukaemia after treatment for Hodgkin's disease1994
Dr Mark Levasseur
Professor Graham Jackson
Dr Jennifer Kernahan
Professor Stephen Proctor
Dr Peter Middleton
et al.
Relapse of acute lymphoblastic leukaemia 14 years after presentation: use of molecular techniques to confirm true re-emergence1994
Dr Penelope Taylor
Professor Graham Jackson
Dr Anne Lennard
Dr Helen Lucraft
Professor Stephen Proctor
et al.
Autologous transplantation in poor risk Hodgkin's disease using high dose melphalan/etoposide conditioning with non-cryopreserved marrow rescue1993
Dr Anne Lennard
Dr Penelope Taylor
Professor Graham Jackson
Professor Stephen Proctor
Peripheral blood stem-cell transplantation versus non-cryopreserved autologous bone-marrow transplantation1993
Dr Peter Middleton
Dr Penelope Taylor
Dr Michael Reid
Professor Graham Jackson
Professor Stephen Proctor
et al.
Alpha interferon gene deletions in adults, children and infants with acute lymphoblastic leukemia1991
Dr Anne Lennard
Professor Graham Jackson
Dr Peter Carey
Dr Peter Middleton
Professor Stephen Proctor
et al.
Secondary acute lymphoblastic leukaemia with 4:11 translocation following treatment for Hodgkin's disease1991
Professor Graham Jackson
Dr Andrea Clarke
Dr Penelope Taylor
Professor Anne Dickinson
Professor Stephen Proctor
et al.
Supernatant cell counts from long-term bone marrow culture correlate with the speed of engraftment following autologous bone marrow transplantation1991
Dr Anne Lennard
Dr Peter Carey
Professor Graham Jackson
Professor Stephen Proctor
An effective oral combination in advanced relapsed Hodgkin’s disease prednisolone, etoposide, chlorambucil and CCNU1990
Professor Graham Jackson
Dr Jonathan Wallis
Dr Anne Lennard
Professor Stephen Proctor
Hydroxyurea-induced acute alveolitis in a Patient with chronic myeloid leukaemia1990
Professor Stephen Proctor
Professor Graham Jackson
Recombinant interferon alfa-2B in refractory idiopathic immune thrombocytopenia: Response1990
Professor Stephen Proctor
Professor Graham Jackson
Dr Peter Carey
Dr Roger Finney
Improvement of platelet counts in steroid-unresponsive idiopathic immune thrombocytopenic purpura after short-course therapy with recombinant alpha 2b interferon1989
Professor Graham Jackson
Dr Peter Carey
Professor Stephen Proctor
Severe renal toxicity due to intermediate-dose methotrexate1989
Professor Stephen Proctor
Professor Graham Jackson
Dr Peter Carey

Short-course alpha-interferon therapy in severe unresponsive immune thrombocytopenic purpura

1988